- AuthorisedTherapeutic confirmatory (Phase III)
MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM
This study is looking at new ways to treat multiple myeloma, a type of blood cancer, in people under 66. It's testing if different treatment plans can better reduce the cancer to very low levels before further treatment. The aim is to find out which approaches work best for patients.
For: Multiple MyelomaBelgium · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment
This study looks at a new combination of medicines, including isatuximab, for people newly diagnosed with multiple myeloma and kidney problems. Researchers want to see how well these treatments help reduce kidney damage and slow down the myeloma.
For: Newly diagnosed patients with multiple myeloma and severe renal impairmentGreece - RecruitingPHASE2
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
This study looks at a new drug combination (Isatuximab, Iberdomide, and Dexamethasone) for people with early-stage, "smouldering" myeloma that has a higher chance of turning into active myeloma. It aims to see if these drugs can stop or slow down the disease's progression.
For: Smouldering MyelomaUnited Kingdom - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase 1/2 trial evaluating isatuximab in combination with pegenzileukin in relapsed or refractory multiple myeloma (RRMM) previously exposed to anti-CD38 and anti-BCMA
This study is looking at a new combination of treatments for multiple myeloma that has come back or isn't responding to current treatments. It aims to find the safest dose of these new drugs and see how well they work together to shrink the cancer or stop it from growing.
For: CancerGreece · Germany · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma (GMMG HD8/ DSMM XIX)
This study looks at new ways to treat multiple myeloma, a type of blood cancer. It compares giving a new medicine called isatuximab in two different ways (through a drip or an injection) alongside standard treatments. The aim is to see if an injection works as well as a drip.
For: Multiple MyelomaAustria · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Isatuximab in type I cryoglobulinemia: A prospective pilot study / ICE STUDY
This study is looking at a new medicine called Isatuximab for people with a rare condition called type I cryoglobulinemia. It aims to see how well the medicine can reduce symptoms of blood vessel inflammation (vasculitis) and if it is safe to use. This is an early-stage study.
For: Isatuximab in type I cryoglobulinaemia: A prospective pilot studyFrance